ELTX — Elicio Therapeutics Inc.
NASDAQ · Healthcare · Biotechnology
$2.56
-$0.14 (-5.19%)
Elicio Therapeutics Inc. (ELTX) is a biotechnology company listed on NASDAQ. It is led by Robert T. Connelly, based in 451 D Street, Boston, MA, United States, 02210, with about 32 employees. Elicio Therapeutics, Inc., a clinical-stage biotechnology company, develops immunotherapies for the treatment of cancer. Its lead product candidate is ELI-002, a multivalent lymph node"targeted amphiphile (AMP) peptide vaccine that is in Phase II clinical trial to target seven Kirsten rat sarcoma viral oncogene homolog driver mutations. The company also develops ELI-007, a multivalent lymph node"targeted AMP peptide vaccine in preclinical studies for the treatment of mutant b-raf murine sarcoma viral oncogene homolog B1-driven cancers; and ELI-008, a multivalent lymph node"targeted AMP peptide vaccine in preclinical studies for use in the treatment of mutated tumor protein p53 expressing cancers. Elicio Therapeutics, Inc. is headquartered in Boston, Massachusetts.
Net income was -$10.1M. ELTX currently screens at market cap $132.3M.
Use this ELTX page for company research — sector, financials, and the latest filing takeaway — not a live tape. The session quote (last, range, volume) lives on the ELTX quote page. Cached 10-K, 10-Q, 8-K, and Form 4 exhibits are on the ELTX SEC filings page. Lician reads the product cache first so this HTML stays unique to Elicio Therapeutics Inc. even when a live quote feed is slow.
About Elicio Therapeutics Inc.
Elicio Therapeutics, Inc., a clinical-stage biotechnology company, develops immunotherapies for the treatment of cancer. Its lead product candidate is ELI-002, a multivalent lymph node"targeted amphiphile (AMP) peptide vaccine that is in Phase II clinical trial to target seven Kirsten rat sarcoma viral oncogene homolog driver mutations. The company also develops ELI-007, a multivalent lymph node"targeted AMP peptide vaccine in preclinical studies for the treatment of mutant b-raf murine sarcoma viral oncogene homolog B1-driven cancers; and ELI-008, a multivalent lymph node"targeted AMP peptide vaccine in preclinical studies for use in the treatment of mutated tumor protein p53 expressing cancers. Elicio Therapeutics, Inc. is headquartered in Boston, Massachusetts.
ELTX Key Statistics
Market Cap
$132.30M
Volume
16,080
Previous Close
$2.98
Day Range
$3.00 – $3.05
EPS
-$4.25
Revenue
$0.00
Net Income
-$51.90M
Gross Profit
$0.00
Free Cash Flow
$0.00
Employees
32
ELTX Financials
Annual income statement in USD. Latest reported periods first.
| Line | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $2.30M | $28.31M |
| Cost of Revenue | $0.00 | $0.00 | $0.00 | $0.00 |
| Gross Profit | $0.00 | $0.00 | $0.00 | $0.00 |
| Operating Income | $0.00 | $0.00 | $0.00 | $0.00 |
| Net Income | -$51.90M | -$35.20M | -$28.21M | -$54.57M |
| EPS (Diluted) | -$4.25 | -$6.96 | -$89.27 | -$1.93 |
Total Assets
$28.18M
Total Debt
$0.00
Shareholders' Equity
$0.00
Cash & Equivalents
$17.62M
Operating Cash Flow
-$37.07M
Free Cash Flow
$0.00
Elicio Therapeutics Inc. Company Information
- CEO, President & Director
- Robert T. Connelly
- Headquarters
- 451 D Street, Boston, MA, United States, 02210
- Website
- elicio.com
- Phone
- (857) 209-0050
- IPO / Founded
- 2021-02-05
- Sector
- Healthcare
- Industry
- Biotechnology